Trials / Recruiting
RecruitingNCT05237388
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- Duke University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the drug, baricitinib, is safe and effective in reducing high levels of albumin in the urine (albuminuria) in African American/Blacks with APOL1- associated focal segmental glomerulosclerosis (FSGS) and non-diabetic APOL1-associated chronic kidney disease due to hypertension (HTN-CKD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baricitinib | One pill daily |
| DRUG | Placebo | Baricitinib placebo pill |
Timeline
- Start date
- 2023-04-20
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2022-02-14
- Last updated
- 2025-03-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05237388. Inclusion in this directory is not an endorsement.